These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 22070215)

  • 21. Costs of inpatient treatment for multi-drug-resistant tuberculosis in South Africa.
    Schnippel K; Rosen S; Shearer K; Martinson N; Long L; Sanne I; Variava E
    Trop Med Int Health; 2013 Jan; 18(1):109-16. PubMed ID: 23170876
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness of bedaquiline or delamanid plus background regimen for multidrug-resistant tuberculosis in a high-income intermediate burden city of China.
    Fan Q; Ming WK; Yip WY; You JHS
    Int J Infect Dis; 2019 Jan; 78():44-49. PubMed ID: 30342251
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Direct costs of managing adverse drug reactions during rifampicin-resistant tuberculosis treatment in South Africa.
    Schnippel K; Firnhaber C; Berhanu R; Page-Shipp L; Sinanovic E
    Int J Tuberc Lung Dis; 2018 Apr; 22(4):393-398. PubMed ID: 29562986
    [TBL] [Abstract][Full Text] [Related]  

  • 24. What is the cost of diagnosis and management of drug resistant tuberculosis in South Africa?
    Pooran A; Pieterson E; Davids M; Theron G; Dheda K
    PLoS One; 2013; 8(1):e54587. PubMed ID: 23349933
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Scaling up target regimens for tuberculosis preventive treatment in Brazil and South Africa: An analysis of costs and cost-effectiveness.
    Nsengiyumva NP; Campbell JR; Oxlade O; Vesga JF; Lienhardt C; Trajman A; Falzon D; Den Boon S; Arinaminpathy N; Schwartzman K
    PLoS Med; 2022 Jun; 19(6):e1004032. PubMed ID: 35696431
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost per patient of treatment for rifampicin-resistant tuberculosis in a community-based programme in Khayelitsha, South Africa.
    Cox H; Ramma L; Wilkinson L; Azevedo V; Sinanovic E
    Trop Med Int Health; 2015 Oct; 20(10):1337-45. PubMed ID: 25975868
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Economic implications of novel regimens for tuberculosis treatment in three high-burden countries: a modelling analysis.
    Ryckman TS; Schumacher SG; Lienhardt C; Sweeney S; Dowdy DW; Mirzayev F; Kendall EA
    Lancet Glob Health; 2024 Jun; 12(6):e995-e1004. PubMed ID: 38762299
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost Analysis of Tuberculosis Diagnosis in Cambodia with and without Xpert
    Pallas SW; Courey M; Hy C; Killam WP; Warren D; Moore B
    Appl Health Econ Health Policy; 2018 Aug; 16(4):537-548. PubMed ID: 29862440
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness of adding bedaquiline to drug regimens for the treatment of multidrug-resistant tuberculosis in the UK.
    Wolfson LJ; Walker A; Hettle R; Lu X; Kambili C; Murungi A; Knerer G
    PLoS One; 2015; 10(3):e0120763. PubMed ID: 25794045
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost effectiveness analysis of strategies for tuberculosis control in developing countries.
    Baltussen R; Floyd K; Dye C
    BMJ; 2005 Dec; 331(7529):1364. PubMed ID: 16282379
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Economic evaluation of a shortened standardised treatment regimen of antituberculosis drugs for patients with multidrug-resistant tuberculosis (STREAM): study protocol.
    Gama E; Madan J; Langley I; Girma M; Evans D; Rosen S; Squire SB
    BMJ Open; 2016 Oct; 6(10):e014386. PubMed ID: 27798041
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reflecting the Health Opportunity Costs of Funding Decisions Within Value Frameworks: Initial Estimates and the Need for Further Research.
    Ochalek J; Lomas J
    Clin Ther; 2020 Jan; 42(1):44-59.e2. PubMed ID: 31955967
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J; Jones J; Takeda A; Davidson P; Price A
    Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Feasibility and cost-effectiveness of treating multidrug-resistant tuberculosis: a cohort study in the Philippines.
    Tupasi TE; Gupta R; Quelapio MI; Orillaza RB; Mira NR; Mangubat NV; Belen V; Arnisto N; Macalintal L; Arabit M; Lagahid JY; Espinal M; Floyd K
    PLoS Med; 2006 Sep; 3(9):e352. PubMed ID: 16968123
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost of treatment for multidrug-resistant tuberculosis in South Korea.
    Kang YA; Choi YJ; Cho YJ; Lee SM; Yoo CG; Kim YW; Han SK; Shim YS; Yim JJ
    Respirology; 2006 Nov; 11(6):793-8. PubMed ID: 17052310
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Impact and Cost-Effectiveness of a Four-Month Regimen for First-Line Treatment of Active Tuberculosis in South Africa.
    Knight GM; Gomez GB; Dodd PJ; Dowdy D; Zwerling A; Wells WA; Cobelens F; Vassall A; White RG
    PLoS One; 2015; 10(12):e0145796. PubMed ID: 26717007
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The epidemiologic impact and cost-effectiveness of new tuberculosis vaccines on multidrug-resistant tuberculosis in India and China.
    Weerasuriya CK; Harris RC; McQuaid CF; Bozzani F; Ruan Y; Li R; Li T; Rade K; Rao R; Ginsberg AM; Gomez GB; White RG
    BMC Med; 2021 Feb; 19(1):60. PubMed ID: 33632218
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Economic evaluation of short treatment for multidrug-resistant tuberculosis, Ethiopia and South Africa: the STREAM trial.
    Madan JJ; Rosu L; Tefera MG; van Rensburg C; Evans D; Langley I; Tomeny EM; Nunn A; Phillips PP; Rusen ID; Squire SB;
    Bull World Health Organ; 2020 May; 98(5):306-314. PubMed ID: 32514196
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost minimization analysis of line probe assay for detection of multidrug-resistant tuberculosis in Arkhangelsk region of Russian Federation.
    Bogdanova EN; Mariandyshev AO; Balantcev GA; Eliseev PI; Nikishova EI; Gaida AI; Enarson D; Detjen A; Dacombe R; Phillips PPJ; Squire SB; Gospodarevskaya E
    PLoS One; 2019; 14(1):e0211203. PubMed ID: 30695043
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.